MODULATE
22 Dec 2020
Trial Summary
This Phase II research project will test the efficacy, safety, and tolerability of an experimental drug combination: either nivolumab and BBI608 or nivolumab and BNC105 in patients with metastatic colorectal cancer who have previously failed standard of care treatment.
Acronym:
MODULATE
ACTRN/NCT /ethics:
NCT03647839
Scientific title:
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Sponsor / Cooperative group:
AGITG
Trial & Patient Characteristics
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2018-09-06 |
| Anticipated End Date | 2022-08-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Recruitment on Hold |
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Nimit Singhal |
| Recruitment Status | Recruitment on Hold |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Chris Karapetis |
| Recruitment Status | Recruiting |